SBI Securities Co. Ltd. Buys Shares of 34,485 Novavax, Inc. (NASDAQ:NVAX)

SBI Securities Co. Ltd. bought a new stake in Novavax, Inc. (NASDAQ:NVAX) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 34,485 shares of the biopharmaceutical company’s stock, valued at approximately $277,000.

Several other large investors have also recently bought and sold shares of the company. Bank of New York Mellon Corp raised its position in Novavax by 0.4% in the fourth quarter. Bank of New York Mellon Corp now owns 436,451 shares of the biopharmaceutical company’s stock valued at $3,509,000 after purchasing an additional 1,664 shares during the last quarter. Victory Capital Management Inc. raised its position in Novavax by 12.0% in the third quarter. Victory Capital Management Inc. now owns 19,292 shares of the biopharmaceutical company’s stock valued at $244,000 after purchasing an additional 2,072 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Novavax by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 33,965 shares of the biopharmaceutical company’s stock valued at $273,000 after purchasing an additional 3,174 shares during the last quarter. Spire Wealth Management bought a new position in Novavax in the fourth quarter valued at about $29,000. Finally, KBC Group NV raised its position in Novavax by 97.0% in the fourth quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company’s stock valued at $64,000 after purchasing an additional 3,917 shares during the last quarter. 53.04% of the stock is currently owned by institutional investors.

Novavax Price Performance

NASDAQ NVAX opened at $7.89 on Thursday. The business has a 50 day simple moving average of $8.47 and a 200 day simple moving average of $9.86. Novavax, Inc. has a one year low of $3.81 and a one year high of $23.86. The stock has a market capitalization of $1.26 billion, a P/E ratio of -3.49, a P/E/G ratio of 2.85 and a beta of 2.14.

Novavax (NASDAQ:NVAX) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.24. The business had revenue of $88.31 million for the quarter, compared to analyst estimates of $85.48 million. During the same period in the prior year, the business earned ($1.44) EPS. Equities analysts expect that Novavax, Inc. will post -1.46 earnings per share for the current year.

Insider Buying and Selling

In other Novavax news, Director James F. Young sold 5,400 shares of the firm’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total value of $43,200.00. Following the completion of the sale, the director now owns 51,760 shares of the company’s stock, valued at approximately $414,080. This trade represents a 9.45 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Rachel K. King sold 4,150 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $9.02, for a total value of $37,433.00. Following the completion of the sale, the director now directly owns 14,770 shares of the company’s stock, valued at $133,225.40. This trade represents a 21.93 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 14,150 shares of company stock valued at $119,641 over the last 90 days. Company insiders own 1.00% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on NVAX. HC Wainwright restated a “buy” rating and set a $19.00 price objective on shares of Novavax in a research report on Tuesday, December 10th. BTIG Research began coverage on Novavax in a research report on Friday, February 28th. They set a “buy” rating and a $19.00 price objective for the company. Finally, TD Cowen upgraded Novavax to a “hold” rating in a research report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $18.00.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.